Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA priority review
Fierce Pharma
Bavarian Nordic's $160M PRV price reflects new realities
The value of PRVs appears to be on the rise as concerns mount over declining supplies following the sunset of the rare pediatric disease PRV program.
Angus Liu
Jun 18, 2025 11:47am
FDA 'on track' to meet all PDUFA dates, Marty Makary says
Jun 18, 2025 4:00am
FDA debuts priority review voucher with 2-month timeline goal
Jun 17, 2025 11:59am
Stealth CEO questions FDA rejection of rare disease drug
May 29, 2025 2:27pm
Vertex meets own cystic fibrosis record with next-gen treatment
Feb 5, 2024 7:50pm
FDA gives Madrigal's NASH drug priority review, no AdComm
Sep 13, 2023 10:50am
